Table 1.
Clinical information on the osteosarcoma samples.
| Sample | Sample origin | Patient age/sex | Subtype | Grade1 | Primary location | Metastasis location | Chemotherapy2 | Response3 | Treated sample | Metastasis (months)4 | Follow-up (months)5 | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OS3 | Met | 17/M | Obl/Cho | 4 | Femur | Lung | Yes (SSG II + VI) | NA | Yes | 23 | 45 | DD |
| OS4 | Met | 15/M | Obl | 4 | Femur | Lung | Yes (SSG II) | Poor | Yes | 14 | 37 | DD |
| OS11 | Met | 22/M | Par | 4 | Femur | Multiple6 | No | — | No | 185 | 193 | DD |
| OS12 | Met | 41/M | Obl/Cho | 4 | Femur | Lung | Yes (SSG VI + VIII) | NA | Yes | 9 | 49 | DD |
| OS17 | Met | 18/M | Obl + Cho | 4 | Humerus | Lung | Yes (SSG II + VI) | NA | Yes | 25 | 49 | DD |
| OS18 | Met | 26/M | Obl | 3 | Fibula | Lung | No | — | No | 117 | 353 | DD |
| OS21 | Met | 17/F | Obl | 4 | Femur | Lung | Yes (SSG VIII) | Poor | Yes | MD | 33 | DD |
| OS23 | Met | 11/F | Obl | 4 | Femur | Lung | Yes (SSG VIII) | NA | Yes | MD | 229 | NED |
| OS25 | Met | 19/M | Fbl | 4 | Fibula | Skeleton | Yes (SSG VI + VIII) | NA | Yes | MD | 44 | DD |
| OS32 | Met | 24/M | Fbl | 4 | Tibia | Lung | Yes (SSG VI) | Poor | Yes | 6 | 208 | NED |
| OS53 | Met | 18/M | Obl/Fbl | 4 | Humerus | Multiple7 | Yes (ISG/SSG I) | Poor | Yes | 26 | 68 | DD |
| OS14 | Prim | 14/F | Obl/Fbl | 4 | Femur | Lung | Yes (SSG II) | Poor | Yes | MD | 13 | DD |
| OS15 | Prim | 49/F | Obl | 4 | Costa | Lung | Yes (NA) | NA | No | MD | 3 | DD |
| OS19 | Prim | 16/F | Obl | 4 | Tibia | — | Yes (SSG VIII) | NA | Yes | — | 245 | NED |
| OS20 | Prim | 17/F | Obl/Fbl | 4 | Humerus | Soft tissue | Yes (SSG VIII) | NA | No | 139 | 151 | DD |
| OS29 | Prim | 27/F | Obl | 4 | Pelvis | Lung | No | — | No | MD | 4 | DD |
| OS30 | Prim | 21/F | Obl | 4 | Femur | Lung | Yes (SSG VIII) | NA | No | MD | 162 | NED |
| OS41 | Prim | 11/M | Obl | 4 | Tibia | NA | No | — | No | NA | NA | NA |
| OS47 | Prim | 12/M | SC/Pleo | 4 | Humerus | Lung | Yes (SSG XIV + EURAMOS I) | Good | No | 92 | 124 | NED |
| OS48 | Prim | 50/M | Obl/Fbl | 4 | Tibia | — | Yes (SSG XIV) | NA | No | — | 74 | NED |
| OS50 | Prim | 11/M | Cho | 4 | Femur | — | Yes (SSG XIV) | Poor | No | — | 108 | NED |
| OS51 | Prim | 18/F | Obl/Tel | 4 | Femur | Lung | Yes (ISG/SSG II) | NA | No | MD | 22 | DD |
| OS55 | Prim | 17/F | Obl | 4 | Femur | — | Yes (SSG XIV) | NA | No | — | 91 | NED |
Abbreviations: OS, osteosarcoma; Met, metastasis; Prim, primary tumour; M, male; F, female; Obl, osteoblastic; Cho, chondroblastic; Par, parosteal; Fbl, fibroblastic; SC, spindle cell; Pleo, pleomorphic; Tel, telangiectatic; NA, not available; DD, dead of disease; NED, no evidence of disease.
1Grading is based on a four-tiered system used in the Scandinavian Sarcoma Group (SSG).
2Chemotherapy has been given according to the indicated Scandinavian Sarcoma Group (SSG) protocols, Italian Sarcoma Group/Scandinavian Sarcoma Group (ISG/SSG) protocol or European, and American Osteosarcoma Study Group (EURAMOS) protocol (for more information, see http://www.ssg-org.net/index.htm).
3Histological evaluation.
4Time to first metastasis from diagnosis.
5Time to last follow-up from diagnosis.
6Multiple locations, lung, and lymph node.
7Multiple locations, lung, and skeleton.